摘要
目的 :应用逆转录聚合酶链反应 (RT PCR)法检测确诊小细胞肺癌 (SCLC)患者骨髓、外周血中HuD mRNA的表达 ,分析其临床意义 ,探讨其在检测骨髓微转移中的价值。 方法 :选择病理学确诊为SCLC的初治患者 14例 ,采集骨髓及外周静脉血标本 ,另以 15例非小细胞肺癌 (NSCLC)患者及 12例良性病变患者的骨髓及血标本为对照组。 7例SCLC患者在接受 1～ 2个疗程化疗后再次取骨髓及外周血标本 ,用RT PCR法检测所有标本中HuD mRNA的表达。 结果 :SCLC患者骨髓HuD阳性率 (5 7.1% )显著高于非肿瘤对照组 (16 .7% ) ,P <0 .0 5 ;但与NSCLC对照组差异不明显 (33.3% ) ,P >0 .0 5。SCLC广泛期骨髓HuD阳性率 (85 .7% )高于局限期 (2 8.6 % ) ,P <0 .0 5。外周血标本 :SCLC外周血HuD阳性率 (4 2 .9% )与非肿瘤对照组 (16 .7% )、NSCLC对照组 (33.3% )比较差异均不显著 (均为P >0 .0 5 )。 结论 :SCLC微转移是普遍存在的 ,骨髓微转移的存在与患者的临床分期密切相关。
Objective:To determine the expression of HuD-mRNA in peripheral blood and bone marrow with RT-PCR, analysis the clinical significence of the micrometastases. Methods:Bone marrow and blood micrometastases was conducted in small-cell lung cancer(SCLC) patients without chemotherapy, 15 non-small cell lung cancer(NSCLC) and 12 benign disease patients were also admitted. The presence of micrometastases was investigated by RT-PCR for HuD-mRNA from peripheral blood and bone marrow.Results:Prevalence of HuD in bone marrow in SCLC was higher than that in benign patients(57.1% vs 16.7%,P<0.05); the positive frequency of SCLC was also higher than that of NSCLC, but the difference was not significant(57.1% vs 33.3%, P>0.05). The HuD positive rate was 87.1% in SCLC with extensive stage higher than those of limited stage. The differences of positive rate in blood were not prominent between SCLC, NSCLC and benign patients. The difference was not found between bone marrow and blood in HuD-mRNA expression. Conclusion:Micrometastases in SCLC patient's bone marrow and peripheral blood is very common in SCLC patients regardless of the negative finding in common examinations. Bone marrow micrometastases correlates with extensive stages.
出处
《医学研究生学报》
CAS
2004年第9期808-811,共4页
Journal of Medical Postgraduates
